Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting earnings tomorrow after the bell. Here’s what to look for. Collegium Pharmaceutical beat analysts’ revenue ...

A Russian UAV has struck a nine-storey building in the city of Chernihiv, causing a vehicle in a car park to catch fire. Source: Dmytro Bryzhynskyi, Head of Chernihiv City Military Administration; ...

On March 16, russian occupiers attacked the Chernihiv Region with a ballistic missile and drones. The city council building was hit. This was reported by the head of the Chernihiv Regional Military ...

CHERNIHIV, Ukraine — The 43-year-old Ukrainian actor took to the stage wearing a black leather jacket and with a moustache painted on her face. Ruslana Ostapko was performing in multiple ...

Source: Chernihiv Oblast Military Administration Details: Ukrainian authorities have reported that a Russian First-Person View drone attack is currently underway near the town of Semenivka. The ...

Analysts on Wall Street project that Collegium Pharmaceutical (COLL) will announce quarterly earnings of $1.54 per share in its forthcoming report, representing a decline of 2.5% year over year.

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Collegium Pharmaceutical (COLL – Research Report), with a price target of $36.00. See what stocks are ...

With Most Male Actors at War, a Small Ukrainian Theater Reinvents Itself With an All-Female Cast CHERNIHIV, Ukraine (AP) — The 43-year-old Ukrainian actor took to the stage wearing a black ...

The Neubauer Collegium for Culture and Society has announced nine new projects for 2025-26. Each year Collegium projects bring together University faculty and other researchers to work through ...

The Supreme Court Collegium on Thursday recommended the elevation of Justice Joymalya Bagchi, judge of the Calcutta High Court, to the apex court. The resolution of the Collegium stated that on ...

Collegium Pharmaceutical Inc. is a specialty pharma company with strong cash flow, high EBITDA margins, and a focus on non-abusive painkillers and ADHD drugs. The new CEO has a proven track record ...